



## **GvHGvL 2024**

**Programmkomitee: D Weber, D Wolff, M Edinger, H Poeck, W Herr, HJ Kolb, E Holler**

**Draft August 31,2023**

**Wednesday, March 13:**

### **A and cGvHD Pathophysiology:**

P Reddy: Tissue tolerance (Zusage)

E Meedt: Clonal CD8 in intestinal biopsies (Zusage)

T Winkler: IgA Plasmoblasts and cGvHD (angefragt)

RJ Chakraverty: T cell autoimmunity and cGvHD(angefragt)

### **Acute and cGvHD: Biomarkers: Chair – JLM Ferrara (Zusage)**

G Socie: Integration of biomarkers (Zusage)

J Levine – MAGIC 2024 (Zusage )

S Holtan – CD83 and amphiregulin overexpression as a prognostic biomarker (Zusage)

K Schultz – Results of the ABEL consortium on biomarkers of cGvHD (Zusage)

**Evening discussion/session: Focus on GvHD**

**Thursday, March 14**

**Microbiota and beyond: Where do we go**

R Jenq:: Microbiome remediation therapies to reduce SCT toxicities (Zusage)

D Weber: MAGIC biomarkers and microbiota (Zusage)

E Orberg: Multiomic approach and transkingdom interaction(Zusage)

H Poeck – Metabolites dampening GvH and promoting GvL(Zusage)

N Köhler: Defensine und GvHD (angefragt)

**GvHD: New options for prophylaxis and treatment:**

Floisand: Vedolizumab prophylaxis (angefragt)

Zeiser: GLP1 Agonists (Zusage)

J Schetelig – ATG vs PostTxCy (Zusage)

**Keynote Lecture: – T reg pophlyaxis**

E Meyer – Orca T – update on a new hope for patients (angefragt durch ME)

**Regulatory T cells:**

M Edinger: Pathophysiology and experimental data (angefragt)

M Feuerer: Update on and strategies with Tissue T regs (Zusage)

**Graft-versus-Leukemia. What do we know?**

L Hansmann: TCRs and clonally expanded T cells in myeloma (Zusage)

M Heemskerk: New strategies against minor antigens (Zusage)

K Fleischhauer: HLA-DPB mismatch models (Zusage)

E Ullrich: NK /engineered NK cells and GvL (Zusage)

**HJ Kolb award and lecture**

**Social evening**

**Friday, March 15:**

**Keynote Lecture: M v d Brink** –CAR-T and allogeneic SCT – where do we go (Zusage )

**CAR-T cells – I – focus on myeloid malignancies**

L Gattinoni: Enhancing GvL responses by donor-derived CAR-modified CD8+ T memory stem cells. ( Zusage )

K Schober: TCRs against neoantigens in AML (angefragt)

Hudecek: One fits for all: Upgrade on targets and technologies for CAR-T cells in AML (Zusage)

C Bonini: T cell exhaustion in AML (angefragt)

NN

**CAR-T cells/GvL -II**

D Harrer : CAR-T and type 1 interferon release (Zusage)

JDiPersio: Local HLA upregulation by T cell immunotherapies to improve GvL (Zusage)

L Vago: HLA regulation and immunescape (angefragt)

NN

**Closure and Farewell**